Our goal is to add additional markers to current candidates using our enrichment tech. It helps to remember that up until the ILMN/Solexa machine came online ar

Our goal is to add additional markers to current candidates using our enrichment tech. It helps to remember that up until the ILMN/Solexa machine came online around 2005-6, we could not reliably detect (statistically) MAFs in heterogenous tumor samples below about 20% on the 454 platform (depending on how much cash you threw at the sample). Point is, our enrichment platform allows a deep dive into signals that have yet to be identified as reliable and low variance biomarkers.